These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 12205502)

  • 41. Wrong numbers?
    Nat Biotechnol; 2010 Aug; 28(8):761. PubMed ID: 20697382
    [No Abstract]   [Full Text] [Related]  

  • 42. 25 top health care stocks. Will they lead the next market boom?
    Kane L
    Med Econ; 2001 Apr; 78(7):126-8, 133-6, 140-2. PubMed ID: 11368040
    [No Abstract]   [Full Text] [Related]  

  • 43. Building for an exit (or not).
    Gunning TG
    Nat Biotechnol; 2008 Sep; 26(9):971-3. PubMed ID: 18792427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. South Korean biotechnology--a rising industrial and scientific powerhouse.
    Wong J; Quach U; Thorsteinsdóttir H; Singer PA; Daar AS
    Nat Biotechnol; 2004 Dec; 22 Suppl():DC42-7. PubMed ID: 15583684
    [No Abstract]   [Full Text] [Related]  

  • 45. The emergence of Egyptian biotechnology from generics.
    Abdelgafar B; Thorsteinsdóttir H; Quach U; Singer PA; Daar AS
    Nat Biotechnol; 2004 Dec; 22 Suppl():DC25-30. PubMed ID: 15583680
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmas partner in venture seeking drug discovery tools.
    Mack GS
    Nat Biotechnol; 2008 Sep; 26(9):960-1. PubMed ID: 18779790
    [No Abstract]   [Full Text] [Related]  

  • 47. India's strategy to bridge the public-private divide.
    Jayaraman KS
    Nat Biotechnol; 2005 May; 23(5):523. PubMed ID: 15942982
    [No Abstract]   [Full Text] [Related]  

  • 48. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 49. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 50. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 51. Today's biotech industry in India.
    Suresh N
    Biotechnol J; 2009 Mar; 4(3):291-4. PubMed ID: 19296434
    [No Abstract]   [Full Text] [Related]  

  • 52. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 53. Biotech's wonder ride.
    Rynecki D
    Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
    [No Abstract]   [Full Text] [Related]  

  • 54. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 55. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 57. Introduction: promoting global health through biotechnology.
    Thorsteinsdóttir H; Quach U; Martin DK; Daar AS; Singer PA
    Nat Biotechnol; 2004 Dec; 22 Suppl():DC3-7. PubMed ID: 15583681
    [No Abstract]   [Full Text] [Related]  

  • 58. Gold in the ivory tower: equity rewards of outlicensing.
    Edwards M; Murray F; Yu R
    Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biotechnology in the Medicon Valley.
    Frank L
    Nature; 2002 Dec; 420(6916 Suppl):A27, A29, A31 passim. PubMed ID: 12501124
    [No Abstract]   [Full Text] [Related]  

  • 60. Wrong map: why public science can't really be public.
    Mukherjee S
    New Repub; 2000 May; 222(19):14-5. PubMed ID: 12465651
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.